Roivant Sciences officer proposes $7.12M share sale

Six earlier common-share sales by Mayukh Sukhatme are dated August 14, 17, 18, 19, 20 and 21, 2026.

Available on EDGAR 11/10/2026 - 04:28 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Roivant Sciences Ltd. officer and director Mayukh Sukhatme gave notice of a proposed sale of 173,725 common shares, with an aggregate market value of $7,122,725.00 and an approximate sale date of November 10, 2026. The shares were acquired from the issuer as performance stock units for services rendered on November 10, 2026. Morgan Stanley Smith Barney LLC is named as the broker.

Key Figures

Proposed shares for sale: 173,725 common shares Aggregate market value: $7,122,725.00 Common shares outstanding: 724,561,460 common shares

3 metrics

Proposed shares for sale 173,725 common shares Approximate sale date: November 10, 2026

Aggregate market value $7,122,725.00 Proposed sale

Common shares outstanding 724,561,460 common shares Outstanding share count reported with the proposed sale

Key Terms

Performance Stock Units, Aggregate Market Value, Gross Proceeds

3 terms

Performance Stock Units financial

"Nature of Acquisition Transaction: Performance Stock Units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Aggregate Market Value financial

"Aggregate Market Value: 7122725.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Gross Proceeds: 5280004.05"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares is Mayukh Sukhatme proposing to sell?

Mayukh Sukhatme proposed to sell 173,725 ROIV common shares, with an aggregate market value of $7,122,725.00 and an approximate sale date of November 10, 2026.

What earlier ROIV share sales did Mayukh Sukhatme report?

The listed sales were 144,756 shares on August 21, 17,519 on August 20, 172,899 on August 19, 136,942 on August 18, 284,707 on August 17, and 243,177 on August 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001750050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD.
SEC File Number	001-40782
Address of Issuer	7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	44 207 400 3347
Name of Person for Whose Account the Securities are To Be Sold	MAYUKH SUKHATME
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	173725	7122725.00	724561460	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Performance Stock Units	Issuer			173725	11/10/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/21/2026	144756	5280004.05
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/20/2026	17519	653407.89
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/19/2026	172899	6426356.82
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/18/2026	136942	5029208.64
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/17/2026	284707	10320571.81
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/14/2026	243177	8809767.72

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mayukh Sukhatme
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)